Treatment of Intracranial G422 Glioblastoma with Bone Marrow-Derived Dendritic Cells Pulsed with Tumor Extracts

童鹰,詹仁雅,周永庆,张立煌,姚杭平,杜理安

DOI: https://doi.org/10.3760/j.issn:1001-9030.2003.07.028

2003-01-01

Abstract:Objective To investigate the anti-tumor efficacy of dendritic cell (DC) -based vaccines pulsed with tumor extracts in a mice model of intracranial G422 glioblastoma.Methods 72 adult female mice were treated with subcutaneous injections of either PBS,unpulsed DC,G422 tumor extracts,or DC vaccine.After immunization,spleens of 24 mice were harvested for cell-mediated cytotoxicity assays and other 48 mice were challenged in the brain with G422 tumor cells.Another 48 adult female mice harboring intracranial G422 glioblastomas were treated with subcutaneous injections of either PBS,unpulsed DC,G422 tumor extracts,or DC vaccine.The survival was observed.The mouse brains were removed and examined pathologically when the mice died.Results Immunization using DC vaccine induced G422-specific CTL responses that were statistically significant (P0.01).One group of mice were challenged with G422 tumor cells after receiving either PBS,unpulsed DC,G422 tumor extracts,or DC vaccine and the survival time was (21.42±1.86),(24.00±2.36),(22.75±1.89) and (32.42±3.80) days respectively.Survival was significant prolonged in DC vaccine group (P0.01).The survival of intracranial tumor-bearing mice injected sudcutaneously with DC vaccine was significantly prolonged relative to the survival of controls (P0.05).In the mice treated with PBS,unpulsed dendritic cells,or tumor extracts.The survival time was 17.00±1.62,17.58±1.80 and 16.92±2.20 days,respectively.In contrast,the mice in DC vaccine group had a significantly longer survival time of (22.00±3.12) days.Conclusion DC-based vaccine represented a promising approch to the immunotherapy of gliomas,which can specifically activate antitumor T cells and lead to significantly prolonged survival in tumor -bearing animals.